This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Neurosurgery Journal Published Study Reinforces Value Of High-field IMRI

Stocks in this article: IM IMRS

VISIUS intraoperative MRI significantly enhances amount of complete resection in brain tumors and leads to better patient outcomes

MINNEAPOLIS, April 17, 2014 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that a study published this month in the journal Neurosurgery by the neurosurgical team at Cleveland Clinic adds to growing clinical evidence which validates use of high-field intraoperative MRI (iMRI) as an effective tool for maximizing the amount of surgical resection of gliomas (brain tumors).

Conducted using an IMRIS VISIUS ® Surgical Theatre, the study retrospectively reviewed use of high-field 1.5T (tesla) iMRI on the extent of resection of enhancing (high-grade) and non-enhancing (low-grade) gliomas in 104 surgical cases. This and past studies have indicated a link between increased or more complete removal of some types of tumors and longer life expectancy and quality of life.

Use of iMRI, according to the article, was associated with improvement in the median amount of tumor removal from 94.9 percent before iMRI to a final of 99.6 percent post-surgery after iMRI. Complete resection was possible in 65 percent of patients when iMRI was used compared to 34 percent without iMRI. All resection results were considered statistically significant.

The results reinforce previously published evidence that IMRIS systems with high-field iMRI-guided surgery are more effective in achieving complete resection than conventional surgery using neuronavigation and direct visualization alone.

This published evidence from leading neurosurgical hospitals using iMRI showed that in over 40% of all cases, the surgeon chose to modify their approach based on new information from intraoperative MR imaging that would otherwise not have been available until after completing the procedure. Furthermore, in over 55% of glioma tumor cases, additional brain tumor was identified and resected after imaging. In addition, these centers report significant improvements - about 30 percentage points - in the portion of cases achieving total or complete tumor resection with intraoperative MR compared to cases without it.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs